Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPOX + Sintilimab + IBI305 for Neoadjuvant Gastric/GEJ Cancer
NCT06667050Phase 2Active, not recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Oct 2024
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, bevacizumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by West China Hospital of Sichuan University. Started Oct 2024; status: active, not recruiting.
02
Drugs
sintilimabbevacizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06667050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06667050.